Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 26: 1224-1226, 1980;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sykes, A.
Right arrow Articles by Chard, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sykes, A.
Right arrow Articles by Chard, T.

Clinical Chemistry, Vol 26, 1224-1226, Copyright © 1980 by American Association for Clinical Chemistry

Two-site immunofluorometric assay for pregnancy-specific beta 1- glycoprotein (SP1)

A Sykes and T Chard

We describe an immunoassay for human pregnancy-specific beta 1- glycoprotein by use of fluorescein-labeled antibodies to this protein. The technique is generally similar to that of a "two-site" immunoradiometric assay but has the advantage of stability of tracer and avoidance of radiation hazard. However, the procedure requires relatively large quantities of antibody. Furthermore, the within-assay coefficient of variation (11.8%) is greater than that for radioimmunoassay (6.5%). This results from imprecision of the end-point detection, and some inherent difficulties in optimizing a "two-site" immunometric system. Concentrations of endogenous material as measured by the fluorometric assay are 1.9-fold higher than those obtained with radioimmunoassay, probably because the former detects multiple forms of this heterogeneous material.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1980 by the American Association for Clinical Chemistry.